)
Edge12 Dec 2025
Running on Clouds: The Story of On
The story of how a Swiss runner's pursuit of a new running sensation became On, aiming to be the most premium global sportswear brand worldwide.
Sun Pharma Advanced Research Company
Sun Pharma Advanced Research Company (SPARC) investor relations material
Sun Pharma Advanced Research Company R&D Day 2026 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.R&D Day 2026 summary8 Jan, 2026
Pipeline overview and program updates
Pipeline realigned to focus on oncology and immunology, prioritizing SCD153 for alopecia areata/vitiligo and SVO154/SBO-154 for solid tumors, with over 10 assets in development.
SCD153 is a topical prodrug with Phase 1a completed and Phase 1b ongoing; foam formulation finalized and animal studies in vitiligo underway.
SVO154/SBO-154 is an anti-MUC1 ADC for solid tumors, with Phase 1a dose escalation enrolling across 11 sites in the US, Australia, and India.
Tiller Therapeutics partnership advances SCO-155/TILR-097, granting Tiller exclusive global rights and securing external funding.
Vodobatinib faces resource allocation challenges in a competitive CML market, with ongoing partner engagement and alternate structure exploration.
Clinical trial data and development milestones
SCD153 Phase 1a showed safety and dermal penetration; Phase 1b in alopecia areata is ongoing, with interim readout expected in Q4 2026 and global Phase 2 planned for Q2 2027.
SVO154/SBO-154 Phase 1a has completed two dose cohorts without unexpected safety signals; MTD expected by Q3 2026, with expansion and early proof of concept by H2 2027.
Preclinical data for SCD153 shows dose-dependent inhibition of key chemokines in melanocytes and keratinocytes.
SVO154 demonstrates strong tumor regression in models with high MUC1 expression, supporting patient selection strategy.
Major upcoming milestones include PRV appeal outcome, Tiller license agreement, and multiple IND-enabling studies in 2026.
R&D strategy and innovation priorities
Emphasis on modular, scalable platforms for targeted delivery of multi-modal cancer therapeutics, including ADCs, SMDCs, T-cell engagers, and siRNA nanoparticles.
Focus on non-JAK pathways and rational combinations for autoimmune diseases, with SCD153 positioned as standalone, combination, or maintenance therapy.
Pursuing bispecific ADCs, immune-stimulating payloads, and tri-specific T-cell engagers to address safety and efficacy challenges.
Portfolio optimization and business model flexibility through early-stage licensing, NewCo formation, and equity transactions.
NewCo strategy for pipeline value unlock?
SCD-153/SBO-154 early efficacy expectations?
How will increased clinical spend be funded?
Update on PRV appeal window expiry
Vodobatinib: Final decision timeline
Funding plan completion timeline
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Sun Pharma Advanced Research Company earnings date
Q3 25/269 Feb, 2026
Sun Pharma Advanced Research Company
Next Sun Pharma Advanced Research Company earnings date
Q3 25/269 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Sun Pharma Advanced Research Company Limited is a pharmaceutical research and development company focused on the discovery and advancement of new drug delivery systems, novel drug formulations, and innovative pharmaceutical technologies. The company conducts pre-clinical and clinical research across various therapeutic areas, supporting product innovation and lifecycle extension. Its activities include formulation development, intellectual property management, and collaboration with global partners for commercialization. Sun Pharma Advanced Research Company Limited operates independently of Sun Pharmaceutical Industries Limited. The company is headquartered in Mumbai, India, and its shares are listed on the NSE.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage